GLP1R and chronic kidney disease: As diabetes is a leading cause of CKD, new therapies with glucagon-like peptide-1 receptor agonists (GLP-1-RA) and sodium/glucose cotransporter 2 inhibitors (SGLT2i) showed antihyperglycemic effect, and reduced all-cause mortality and CV mortality.